Chemotherapy after surgery for high-risk uterine leiomyosarcoma
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether chemotherapy after surgery can help prevent uterine leiomyosarcoma from coming back in patients who are at high risk based on a genetic test of their tumor. It is for women with early-stage cancer (stage I) who have had complete surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had surgery for uterine leiomyosarcoma within the last 8 weeks.
- A tumor sample from your surgery must be available for a special genetic test (CINSARC) to check your risk of recurrence.
- You must be between 18 and 75 years old.
- You must be well enough to do daily activities (ECOG performance status 0 or 1).
- You cannot have had chemotherapy for sarcoma or certain other cancers before.
- You must have no signs of cancer spread (metastases) on scans after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two chemotherapy drugs (doxorubicin and trabectedin) given after surgery to prevent uterine leiomyosarcoma from coming back. The goal is to see if this treatment improves outcomes for patients with high-risk disease that has not spread.
This Phase 2 trial studies how well gemcitabine or trabectedin works for people with leiomyosarcoma that cannot be fully removed or has spread. It’s for tumors that have grown or worsened despite prior standard chemotherapy.
This Phase 2 trial studies whether letrozole can help prevent uterine leiomyosarcoma from coming back after surgery. It focuses on people whose tumor shows estrogen receptor positivity.
This trial studies whether adding chemotherapy before surgery helps people with high-risk retroperitoneal (abdominal-area) leiomyosarcoma or liposarcoma. The goal is to improve outcomes while comparing surgery alone versus surgery plus neoadjuvant chemotherapy.
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
This trial uses your tumor's lab-grown organoids to find the most effective personalized treatment for advanced leiomyosarcoma. It aims to match you with a drug that targets your specific cancer.
Hear when a new Leiomyosarcoma Uterus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.